|
James E. Callaway, PhD was appointed Senior Vice President in March 2004, and has been Alzheimer's Program Leader since 1999. As head of Immunotherapy Alzheimer's Disease Clinical Programs, he has primary responsibility for the advancement of anti-amyloid antibody Bapineuzumab (AAB-001) and the active vaccine ACC-001. Since joining Elan in 1995, Dr. Callaway has held several senior positions, including interim head of Global Development; Vice President of Biopharmaceutical Development Services; and Director, Pharmaceutical Development. Prior to joining Elan, he worked at Bayer Pharmaceuticals as Director of Quality Assurance, Development. Dr. Callaway also worked as Associate Director of Biological Process Sciences at SmithKline Beecham Pharmaceuticals and was a Research Scientist at Xoma. Dr. Callaway received his PhD in Biological Chemistry from University of California Los Angeles, and a Bachelor of Science in Chemistry from California State University Chico. | 